Outset Medical (NSDQ:OM) CEO Leslie Trigg took the helm at the dialysis start-up in 2013, moving from an executive-in-residence post at private equity firm Warburg Pincus. Before that she held senior positions at Lutonix, AccessClosure and FoxHollow, helping to position those companies to be acquired by CR Bard, Cardinal Health, and ev3/Covidien, respectively.
This week, in her first stint as a CEO, Trigg led Outset Medical to an IPO, raising $278 million. The company will use the capital to roll out its Tablo hemodialysis system.
In this week’s DeviceTalks Weekly Podcast, Trigg shared several key points, including:
1. While admitting she was disappointed that Outset executives couldn’t conduct a traditional in-person roadshow, Trigg said meeting public investors via Zoom calls was an effective way to assemble investors. She offered a few insights and tips on how to make virtual calls most effective.
2. Outset initially had more modest goals in establishing Tablo as an alternative to traditional dialysis centers. But Trigg credits the team she assembled for helping the start-up develop a bolder, more comprehensive strategy to change how dialysis is delivered in clinical and home settings.
3. The COVID-19 pandemic not only created a new — and perhaps more efficient way — of raising capital. Trigg also sees the pandemic’s pushing more patients toward out-of-clinic care, creating potential tailwinds for Outset and Tablo.
Hear those points and an interview with Doug Teany, COO of Corindus Vascular Robotics, in this week’s DeviceTalks Weekly Podcast.
You’ll also get a rundown of the Top 5 Medtech Stories from Chris Newmarker, executive editor of MassDevice. This week’s Newmarker’s Newsmakers including Hologic, Varian, Smith+Nephew, Avail Medsystems and Outset Medical.
Hundreds of subscribers have already listened to this podcast. Subscribe today so you get these insights first.